Assembling a smallpox biodefense by interrogating 5-substituted pyrimidine nucleoside chemical space

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 201-205

  Fan, Xuesen ^a   Zhang, Xinying ^a   Zhou, Longhu ^a   Keith, Kathy A ^b   Kern, Earl R ^b   Torrence, Paul F ^a  

^a NORTHERN ARIZONA UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Aldehyde; Cowpox virus; Multicomponent reaction; Pyran; Pyrazolone; Vaccinia virus

Indexed keywords

5 (DIMETHOXYMETHYL) 2' DEOXYURIDINE; CIDOFOVIR; DEOXYURIDINE DERIVATIVE; NUCLEOSIDE 5 FORMYL 2' DEOXYURIDINE; PYRAN DERIVATIVE; PYRAZOLONE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; COWPOX VIRUS; PRIORITY JOURNAL; SHORT SURVEY; SMALLPOX; SUBSTITUTION REACTION; VACCINIA VIRUS;

ANIMALS; BIOLOGICAL WARFARE; COWPOX VIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINE NUCLEOSIDES; SMALLPOX; VACCINIA VIRUS;

COWPOX VIRUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 33747147736     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.04.015     Document Type: Short Survey

References (25)

1. Abrahams B.C., and Kaufman D.M. Anticipating smallpox and monkeypox outbreaks: complications of the smallpox vaccine. Neurologist 10 5 (2004) 265-274
2. Ales N.C., and Katial R.K. Vaccines against biologic agents: uses and developments. Respir. Care Clin. N. Am. 10 1 (2004) 123-146
3. Balicer R.D., Davidovitch N., Huerta M., Cohen D., and Grotto I. Smallpox vaccination techniques: considerations and unresolved issues. Harefuah 144 1 (2005) 51-56 (69)
4. Bossi P., Garin D., Combadiere B., Rouleau E., Rigaudeau S., LebrunVignes B., Martinez V., Autran B., and Bricaire F. Risk of smallpox, vaccination, bioterrorism. Presse Med. 34 2 Pt 2 (2005) 177-184
5. Bray M. Viral bioterrorism and antiviral countermeasures. In: Torrence P.F. (Ed). Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats (2005), John Wiley & Sons Inc., New York, NY 17-30
6. Bricaire F., and Bossi P. Vaccinal strategies against smallpox in France. Med. Mal. Infect. 34 1 (2004) 1-5
7. Byrd C.M., Bolken T.C., Mjalli A.M., Arimilli M.N., Andrews R.C., Rothlein R., Andrea T., Rao M., Owens K.L., and Hruby D.E. New class of orthopoxvirus antiviral drugs that block viral maturation. J. Virol. 78 22 (2004) 12147-12156
8. Cassimatis D.C., Atwood J.E., Engler R.M., Linz P.E., Grabenstein J.D., and Vernalis M.N. Smallpox vaccination and myopericarditis: a clinical review. J. Am. Coll. Cardiol. 43 9 (2004) 1503-1510
9. Chen R.T. Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies. Vaccine 22 15-16 (2004) 2047-2053
10. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14 2 (2001) 382-397
11. Eckart R.E., Love S.S., Atwood J.E., Arness M.K., Cassimatis D.C., Campbell C.L., Boyd S.Y., Murphy J.G., Swerdlow D.L., Collins L.C., Riddle J.R., Tornberg D.N., Grabenstein J.D., and Engler R.J. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 44 1 (2004) 201-205
12. Ein D., Gruchalla R., Baker J.R., Bellanti J.A., Engler R.A., Jones J.F., Martin B.L., and Routes J.M. Pre-event smallpox vaccination and postevent exposure and disease: a report of the Joint Task Force on Smallpox Vaccination for Allergists. Ann. Allergy Asthma Immunol. 94 1 (2005) 4-7
13. Esposito J.J., and Fenner F. Poxviruses. In: Knipe D.M., and Howley P.M. (Eds). Fileds Virology (2001), Lippincott Williams & Wilkins, Philadelphia 2885-2921
14. Fauci A.S., and Challberg M.D. Host-based antipoxvirus therapeutic strategies: turning the tables. J. Clin. Invest. 115 2 (2005) 231-233
15. Guharoy R., Panzik R., Noviasky J.A., Krenzelok E.P., and Blair D.C. Smallpox: clinical features, prevention, and management. Ann. Pharmacother. 38 3 (2004) 440-447
16. Harrop R., Ryan M.G., Golding H., Redchenko I., and Carroll M.W. Monitoring of human immunological responses to vaccinia virus. Methods Mol. Biol. 269 (2004) 243-266
17. Keith K.A., Hitchcock M.J., Lee W.A., Holy A., and Kern E.R. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 47 7 (2003) 2193-2198
18. Randall A.Z., Baldi P., and Villarreal L.P. Structural proteomics of the poxvirus family. Artif. Intell. Med. 31 2 (2004) 105-115
19. Reeves P.M., Bommarius B., Lebeis S., McNulty S., Christensen J., Swimm A., Chahroudi A., Chavan R., Feinberg M.B., Veach D., Bornmann W., Sherman M., and Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 11 7 (2005) 731-739
20. Su J.R. Emerging viral infections. Clin. Lab. Med. 24 3 (2004) 773-795 (vii)
21. Torrence P.F. Introduction: pestilence, plague, bioterrorism. In: Torrence P.F. (Ed). Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats (2005), John Wiley & Sons Inc., New York, NY 3-16
22. Torres-Velez F., and Brown C. Emerging infections in animals-potential new zoonoses?. Clin. Lab. Med. 24 3 (2004) 825-838 (viii)
23. Tseng C.K. Overview of antiviral drug discovery and development. In: Torrence P.F. (Ed). Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats (2005), John Wiley & Sons Inc., New York, NY 31-82
24. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., De Clercq E., Jones K., Hruby D., and Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79 20 (2005) 13139-13149
25. Yang H., Kim S.K., Kim M., Reche P.A., Morehead T.J., Damon I.K., Welsh R.M., and Reinherz E.L. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115 2 (2005) 379-387